Medical Hypotheses
Volume 58, Issue 3 , Pages 198-202 , March 2002

Postencephalitic Parkinson's disease, amyotrophic lateral sclerosis on Guam and influenza revisited: focusing on neurofibrillary tangles and the trail of tau

Received 8 May 2000 ,Accepted 5 September 2000.

References 

  1. Patterson KD, Pyle GF. The geography and mortality of the 1918 influenza pandemic. Bull Hist Med. 1991;65:4–21
  2. Maurizi C. P. Why was the 1918 influenza pandemic so lethal? The possible role of a neurovirulent neurominidase. Med Hypotheses. 1985;16:1–5
  3. Maurizi C. P. Was a neurovirulent influenza virus the cause of Parkinson-dementia and amyotrophic lateral sclerosis on Guam?. Med Hypotheses. 1987;23:325–326
  4. Maurizi C. P. Influenza caused epidemic encephalitis (encephalitis lethargica): The circumstantial evidence and a challenge to the naysayers. Med Hypotheses. 1989;28:139–142
  5. Markesbery W. R. Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med. 1997;23:134–147
  6. Skinner DC, Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vien blood circulating through the choroid plexus. Endocrinology. 1999;140:4399–4405
  7. Liu R, Zhou J, van H, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-e4/4 Genotype. J Clin Endocrinol Metab. 1999;84:323–327
  8. Maurizi C. P. Loss of intraventricular fluid melatonin can explain the neuropathology of Alzheimer's disease. Med Hypotheses. 1997;49:153–158
  9. Brusco LI, Marquez M, Cardinali DP. Monozygotic twins with Alzheimer's disease treated with melatonin: Case Report. J Pineal Res. 1998;25:260–263
  10. Brusco LI, Marquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett. 1998;19:111–115
  11. Ishiguro K, Ohno H, Arai H. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett. 1999;270:91–94
  12. Singhrao SK, Neal JW, Piddlesden SJ, Newman GR. New immunocytochemical evidence for a neuronal/oligodendroglial origin of corpora amylacea. Neuropath Applied Neurobiol. 1994;20:66–73
  13. Sunderland T, Wolozin B, Galasko D. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry. 1999;46:750–755
  14. Maurizi CP. A cycle of cerebrospinal fluid: supporting evidence and theoretical considerations. Med Hypotheses. 2000;54:417–422
  15. Ishii T, Nakamura Y. Distribution and ultrastructure of Alzheimer' neurofibrillary tangles in postencephalitic parkinsonism of Economo type. Acta Neuropathol (Berl). 1981;55:59–62
  16. Wong KT, Allen IV, McQuaid S, McConnell R. An immunohistochemical study of neurofibrillary tangle formation in post-encephalitic Parkinsonism. Clin Neuropathol. 1996;15:22–25
  17. Buce-Sherrer V, Buce L, Leveugle B. Pathological tau proteins in postencephalitic parkinsonism: Comparison with Alzheimer's disease and other neurodegenerative disorders. Ann Neurol. 1997;42:356–359
  18. Poskanzer DC, Schwab RS. Cohort analysis of Parkinson's syndrome. J Chron Dis. 1963;16:961–973
  19. Elizan TS, Tersaki PI, Yahr MD. HLA-B14 antigen and postencephalitic Parkinson's disease. Arch Neurol. 1980;37:542–544
  20. Mawal-Dewan M, Schmidt ML, Balin B, Perl DP, Lee VM, Trojanowski J. Identification of phosphorylation sites in PHF-TAU from patients with Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex. J Neuropath Exp Neurol. 1996;55:1051–1059
  21. Stone R. Guam: Deadly disease dying out. Science. 1993;261:424–426
  22. Hoffman PM, Robbins DS, Nolte MT, Gibbs CJ, Gajdusek DC. Cellular immunity in Guamanians with amyotrophic lateral sclerosis and parkinsonism-dementia. N Engl J Med. 1978;299:680–685
  23. Savory J, Jagannatha KSR, Huang Y, Letada PR, Herman MM. Age-related hippocampal changes in Bcl-2:Bax Ratio, oxidative stress, redox-active iron and apoptosis associated with aluminum-induced neurodegeneration: Increased susceptibility with aging. Neurotoxicology. 1999;20:805–818
  24. Blass JP, Baker AC, Ko L, Black RS. Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol. 1990;47:864–869
  25. Hennet T, Peterhas E, Stocker R. Alterations of antioxidant defences in lung and liver of mice infected with influenza A virus. J Gen Virol. 1992;73:39–46
  26. Mileva M, Tancheva L, Bakalava R, Galabov A, Savov V, Ribarov S. Effect of vitamin E on lipid peroxidation and liver monooxygenase activity in experimental influenza virus infection. Toxicol Lett. 2000;114:39–45
  27. Peterhans E. Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation. J Nutr. 1997;127:962S–965S
  28. Taubenberger JK, Reid AH, Kraftt AE, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 “Spanish” influenza virus. Science. 1997;275:1793–1796
  29. Reid AH, Fanning TJ, Hultin JV, Taubenberger JK. Origin and evolution of the 1918 “Spanish” influenza virus hemagglutinin gene. Proc Natl Acad Sci USA. 1999;96:1651–1656
  30. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: A pattern of changing age distribution. J Infect Dis. 1998;178:53–60
  31. Pyle GF. The Diffusion of Influenza. New Jersey: Rowan and Littlefield; 1986; p. 64
  32. Torvik A, Meen D. Distribution of brain stem lesions in postencephalitic parkinsonism. Acta Neurol Scand. 1966;42:415–425
  33. Oyanagi K, Wada M. Neuropathology of parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam: an update. J Neurol. 1999;246:II/19–II/27
  34. Bassoe H. T. So-called lethargic encephalitis. Arch Neurol Psychiatry. 1919;1:799–802
  35. Hermodsson s. Orthomyxovirus (influenza viruses). In:  Lycke E,  Noreby E editor. Textbook of Medical Virology. London: Butterworths; 1983;p. 265

PII: S0306-9877(00)91224-6

doi: 10.1054/mehy.2000.1224

Medical Hypotheses
Volume 58, Issue 3 , Pages 198-202 , March 2002

Article Tools